Table 6.
Drug resistance and mutations of HIV infections with virological failure in Hefei from 2018 to 2019.
| Antiretroviral Drug | Number | % | HIV Drug Resistance Mutations (n, %) |
|---|---|---|---|
| Total | 49 | 38.6 | |
| PIs | 3 | 2.4 | |
| ATV | 2 | 1.6 | M46I (2, 1.6), I54V (2, 1.6), L76V (1, 0.8), V82A (2, 1.6), L10F (2, 1.6) |
| DRV | 1 | 0.8 | |
| FPV | 2 | 1.6 | |
| IDV | 2 | 1.6 | |
| LPV/r | 2 | 1.6 | |
| NFV | 2 | 1.6 | |
| SQV | 2 | 1.6 | |
| TPV | 3 | 2.4 | |
| NRTIs | 37 | 29.1 | |
| ABC | 36 | 28.3 | D67N/T (9, 7.1), K70R/E (8, 6.3), M184V (31, 24.4), T215F/Y (10, 7.9), K219Q/E/R (7, 5.5), K65R (9, 7.1), K70Q (2, 1.6), Y115F (7, 5.5), A62V (3, 2.4), L74I (3, 2.4), M41L (5, 3.9), V75M/I (3, 2.4), E44A (1, 0.8), L210L/W (1, 0.8) |
| AZT | 11 | 8.7 | |
| D4T | 25 | 19.7 | |
| DDI | 27 | 21.3 | |
| FTC | 36 | 28.3 | |
| 3TC | 36 | 28.3 | |
| TDF | 22 | 17.3 | |
| NNRTIs | 46 | 36.2 | |
| DOR | 36 | 28.3 | V179D/E (9, 7.1), Y181C (14, 11.0), K101E (8, 6.3), G190S/A/E (13, 10.2), K103N/S (20, 15.7), E138A (7, 5.5), H221Y (6, 4.7), M230L (3, 2.4), V106M/I (13, 10.2), F227L (2, 1.6), A98G (3, 2.4), P225H (3, 2.4), V108I (2, 1.6), Y188L (2, 1.6), L234I (2, 1.6) |
| EFV | 45 | 35.4 | |
| ETR | 24 | 18.9 | |
| NVP | 45 | 35.4 | |
| RPV | 31 | 24.4 |
PIs, protease inhibitors; NRTIs, nucleoside reverse transcriptase inhibitors; NNRTIs, non-nucleoside reverse transcriptase inhibitors. ATV, atazanavir; DRV, darunavir; FPV, fosamprenavir; IDV, indinavir; LPV/r, lopinavir/ritonavir; NFV, nelfinavir; SQV, saquinavir; TPV, tipranavir; ABC, abacavir; AZT, zidovudine; D4T, stavudine; DDI, didanosine; FTC, emtricitabine; 3TC, lamivudine; TDF, tenofovir disoproxil; DOR, dorivirine; EFV, efavirenz; ETR, etravirine; NVP, nevirapine; RPV, rilpivirine.